These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 23322588)
21. Economic Value of Pharmacogenetic Testing for Cancer Drugs with Clinically Relevant Drug-Gene Associations: A Systematic Literature Review. Faruque F; Noh H; Hussain A; Neuberger E; Onukwugha E J Manag Care Spec Pharm; 2019 Feb; 25(2):260-271. PubMed ID: 30698084 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada. Meyers DE; Jenei K; Chisamore TM; Gyawali B JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606 [TBL] [Abstract][Full Text] [Related]
23. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada. Li YYR; Mai H; Trudeau ME; Mittmann N; Chiasson K; Chan KKW; Cheung MC Curr Oncol; 2020 Oct; 27(5):e495-e500. PubMed ID: 33173389 [TBL] [Abstract][Full Text] [Related]
24. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making. Tai TA; Latimer NR; Benedict Á; Kiss Z; Nikolaou A Value Health; 2021 Apr; 24(4):505-512. PubMed ID: 33840428 [TBL] [Abstract][Full Text] [Related]
25. Twenty years of using economic evaluations for drug reimbursement decisions: what has been achieved? Drummond M J Health Polit Policy Law; 2013 Dec; 38(6):1081-102. PubMed ID: 23974475 [TBL] [Abstract][Full Text] [Related]
26. Economic and quality of life outcomes: the four-step pharmacoeconomic research model. Arikian SR; Suver J; Einarson T; Doyle J Oncology (Williston Park); 1995 Nov; 9(11 Suppl):33-6. PubMed ID: 8608054 [TBL] [Abstract][Full Text] [Related]
27. New Drug Reimbursement and Pricing Policy in Taiwan. Chen GT; Chang SC; Chang CJ Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659 [TBL] [Abstract][Full Text] [Related]
28. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea. Bae G; Bae EY; Bae S Health Policy; 2015 May; 119(5):577-87. PubMed ID: 25666339 [TBL] [Abstract][Full Text] [Related]
29. European perspective on the costs and cost-effectiveness of cancer therapies. Drummond MF; Mason AR J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939 [TBL] [Abstract][Full Text] [Related]
30. [Methodology of pharmacoeconomic studies in oncology]. Ballatori E Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873 [TBL] [Abstract][Full Text] [Related]
31. Pharmacoeconomic evaluation in Ireland: a review of the process. Tilson L; O'Leary A; Usher C; Barry M Pharmacoeconomics; 2010; 28(4):307-22. PubMed ID: 20222754 [TBL] [Abstract][Full Text] [Related]
32. COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008. Ismail Z; Peacock SJ; Kovacic L; Hoch JS Int J Technol Assess Health Care; 2017 Jan; 33(4):481-486. PubMed ID: 28871898 [TBL] [Abstract][Full Text] [Related]
33. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer. McCullagh L; Schmitz S; Barry M; Walsh C Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453 [TBL] [Abstract][Full Text] [Related]
34. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions. Wallerstedt SM; Henriksson M Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234 [TBL] [Abstract][Full Text] [Related]
35. Guidelines for conducting pharmaceutical budget impact analyses for submission to public drug plans in Canada. Marshall DA; Douglas PR; Drummond MF; Torrance GW; Macleod S; Manti O; Cheruvu L; Corvari R Pharmacoeconomics; 2008; 26(6):477-95. PubMed ID: 18489199 [TBL] [Abstract][Full Text] [Related]
36. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Cleemput I; van Wilder P; Huybrechts M; Vrijens F Value Health; 2009 Jun; 12(4):441-9. PubMed ID: 19900251 [TBL] [Abstract][Full Text] [Related]
37. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia. Ball G; Levine MAH; Thabane L; Tarride JE Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879 [TBL] [Abstract][Full Text] [Related]
38. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. Henry D; Taylor C Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632 [TBL] [Abstract][Full Text] [Related]
39. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer. Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379 [TBL] [Abstract][Full Text] [Related]
40. Differences in cancer drug assessment between Spain and the United Kingdom. Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]